Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

96 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-09-05

Study Completion Date

2019-09-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical study is designed as a multi-center, randomized, double-blind, placebo-controlled, parallel design, prospective, phase II clinical trial.

An eligible subject who meets inclusion and exclusion criteria is randomly assigned to three groups: study group 1 (GV1001 0.56 mg), study group 2 (GV1001 1.12 mg) or placebo group. A randomized subject is administered either GV1001 or placebo in a total of 14 times and will be evaluated for the efficacy and safety at week of 24.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD)

NCT03959553

Moderate Alzheimer's Disease

WITHDRAWN PHASE2

GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)

NCT05189210

Mild to Moderate Alzheimer's Disease

COMPLETED PHASE2

Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease

NCT02097056

Alzheimer's Disease

COMPLETED PHASE4

A Phase I Clinical Study, Randomized, Single-blind, Placebo-controlled, Multiple Doses, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects.

NCT02178124

Alzheimer Disease

COMPLETED PHASE1

GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)

NCT05303701

Moderate to Severe Alzheimer's Disease

NOT_YET_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

GV1001 0.56 mg, 1.12 mg or placebo is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.

1. Control group (placebo): 30 subjects
2. Study group 1 (GV1001 0.56 mg): 30 subjects
3. Study group 2 (GV1001 1.12 mg): 30 subjects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

Normal saline 0.9%

Group Type PLACEBO_COMPARATOR

Normal Saline 0.9%

Intervention Type DRUG

Normal saline 0.9% is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.

Study group 1

GV1001 0.56 mg

Group Type EXPERIMENTAL

GV1001 0.56 mg

Intervention Type DRUG

GV1001 0.56 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.

Study group 2

GV1001 1.12 mg

Group Type EXPERIMENTAL

GV1001 1.12 mg

Intervention Type DRUG

GV1001 1.12 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Normal Saline 0.9%

Normal saline 0.9% is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.

Intervention Type DRUG

GV1001 0.56 mg

GV1001 0.56 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.

Intervention Type DRUG

GV1001 1.12 mg

GV1001 1.12 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NS 0.9% Tertomotide Tertomotide

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 55 to 85 years of age
2. A patient who satisfies diagnostic criteria for dementia in DSM-IV
3. Probable Alzheimer's disease in NINCDS-ADRDA
4. K-MMSE ≤ 19 at screening and randomization visit
5. GDS 5\~6 stage
6. MRI or CT scan within 12 months prior to screening visit that proves Alzheimer's disease without any other disease that may cause dementia
7. A patient taking stable doses of donepezil for more than 3 months before screening visit
8. A patient who are able to visit a hospital (including inpatient and outpatient based) and receive cognitive and other tests
9. A patient with a caregiver who can accompany all visits and supervise the subject's compliance with the procedures and study drug prescribed in the protocol, and provide detailed information about the patient
10. Written informed consent by a patient or legal representative

Exclusion Criteria

1. Any other cause of dementia shown by CT / MRI findings and neurological examination within 12 months of screening visit

* Possible, probable or definite vascular dementia according to the NINDS-AIREN
* Other central nervous system diseases that may cause cognitive impairment (cerebrovascular disease including cerebrovascular dementia, Parkinsonism, Huntington's disease, subdural hematoma, normal pressure hydrocephalus, brain tumor, Creutzfeldt-Jakob disease, etc.)
* Neurological deficits such as delusions, delirium, epilepsy
2. Vitamin B12, folic acid, syphilis serology, and thyroid stimulating hormone (TSH) results are thought to contribute to the severity of dementia or cause dementia
3. A patient who are considered ineligible for this study by investigator due to concurrent or history of significant psychiatric conditions (eg. schizophrenia or bipolar affective disorder)
4. A patient with a history of known or suspected seizures including febrile seizures, a history of significant head trauma with loss of consciousness or recent unconsciousness that is not explained
5. A patient with acute or unstable cardiovascular disease, active peptic ulcer, uncontrolled hypertension, uncontrolled diabetes or insulin dependent patients or any medical condition that may interfere with the completion of clinical trials
6. Hypersensitivity to investigational medicinal products
7. History of alcohol, substance abuse or dependence (except nicotine dependence) within the last 2 years
8. Concurrent malignancies or invasive cancers diagnosed within the past 5 years except for non-metastatic basal cell carcinoma or squamous cell carcinoma of skin, in situ carcinoma of the uterine cervix or non-metastatic prostate cancer
9. Renal impairment (creatinine clearance (CLcr) \<30 mL / min)
10. Severe liver dysfunction (ALT or AST\> 2 times the upper limit of normal)
11. A patient taking other drugs other than donepezil to treat Alzheimer's disease or other cognitive impairment
12. A patient taking other drugs other than anticholinergic drugs, cholinergic drugs (local usages are allowable, such as pilocarpine eye drops), antidepressants (tricyclic antidepressant, MAO inhibitor) antipsychotics, donepezil to treat Alzheimer's disease
13. Women at childbearing age who do not consent using medicinally acceptable contraception (such as surgical sterilization, intrauterine contraceptive device, condom or diaphragm, an injectable or inserted contraceptive) during the study
14. Pregnancy or breast feeding
15. A patient who participated in other clinical trials within 4 weeks prior to this study
16. 35 kg weight or below
17. A patient who had experienced this study drug
18. A patient who had participated in a clinical trial for Alzheimer dementia vaccine within last 6 months
19. Any other patients who are considered to be ineligible for this study by an investigator

Minimum Eligible Age

55 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No